BERKELEY HEIGHTS, N.J., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the US Patent and Trademark Office (USPTO) issued two patents extending the exclusivity of sapacitabine, the Company’s lead clinical candidate. The first patent claims, among others, methods of treating cancer comprising sapacitabine together with DNA methyltransferase inhibitors, including azacitidine and decitabine. The second patent claims methods of use for sapacitabine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including the dosing regimen used in SEAMLESS, the Company’s ongoing, pivotal, registration-directed, Phase 3 study in front-line elderly AML.
Help employers find you! Check out all the jobs and post your resume.
